share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q:2024财年三季报
美股SEC公告 ·  05/15 13:35

Moomoo AI 已提取核心信息

Incannex Healthcare Inc., a biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced an increase in operating expenses, primarily due to higher research and development costs associated with clinical trials. Research and development expenses rose by $1.6 million compared to the same period in the previous year, reaching $3.3 million. General and administrative expenses also increased by $2.1 million, totaling $4.1 million for the quarter. This rise was attributed to higher salaries and employee benefits, including the issuance of restricted stock, as well as increased legal and accounting expenses following the company's re-domiciliation. Despite these increases, the company benefited from a $1.3 million R&D tax credit. The net loss for the quarter was $6.0 million, a significant increase...Show More
Incannex Healthcare Inc., a biopharmaceutical company, reported its financial results for the quarter ended March 31, 2024. The company experienced an increase in operating expenses, primarily due to higher research and development costs associated with clinical trials. Research and development expenses rose by $1.6 million compared to the same period in the previous year, reaching $3.3 million. General and administrative expenses also increased by $2.1 million, totaling $4.1 million for the quarter. This rise was attributed to higher salaries and employee benefits, including the issuance of restricted stock, as well as increased legal and accounting expenses following the company's re-domiciliation. Despite these increases, the company benefited from a $1.3 million R&D tax credit. The net loss for the quarter was $6.0 million, a significant increase from the $3.6 million loss reported in the previous year. The company's cash position stood at $9.3 million as of March 31, 2024. Incannex Healthcare's business development efforts included the continuation of clinical trials for its drug candidates. Looking ahead, the company plans to further its research and development activities and pursue regulatory approvals for its products.
生物制药公司Incannex Healthcare Inc.公布了截至2024年3月31日的财务报告。该公司营业费用增加,主要由于临床试验相关的研发成本增加。与上一年同期相比,研发费用增长了160万美元,达到330万美元。总行政费用也增加了210万美元,本季度总共为410万美元。这一增长归因于工资和员工福利(包括发行受限股票)增加以及公司重新设立后法律和会计费用的增加。尽管有这些增加,该公司获得了130万美元的研发税收抵免。本季度净损失为600万美元,大幅增加了上一年报告的360万美元的亏损。截至2024年3月31日,该公司的现金状况为930万美元。Incannex Healthcare的业务发展包括继续开展其药物候选品的临床试验。展望未来,公司计划进一步开展研发活动并寻求其产品的监管批准。
生物制药公司Incannex Healthcare Inc.公布了截至2024年3月31日的财务报告。该公司营业费用增加,主要由于临床试验相关的研发成本增加。与上一年同期相比,研发费用增长了160万美元,达到330万美元。总行政费用也增加了210万美元,本季度总共为410万美元。这一增长归因于工资和员工福利(包括发行受限股票)增加以及公司重新设立后法律和会计费用的增加。尽管有这些增加,该公司获得了130万美元的研发税收抵免。本季度净损失为600万美元,大幅增加了上一年报告的360万美元的亏损。截至2024年3月31日,该公司的现金状况为930万美元。Incannex Healthcare的业务发展包括继续开展其药物候选品的临床试验。展望未来,公司计划进一步开展研发活动并寻求其产品的监管批准。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息